A Randomized, Placebo-Controlled, Single and Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BMS-791325 in Healthy Japanese Subjects.
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 17 Jul 2013
At a glance
- Drugs Beclabuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- 17 Jul 2013 Planned end date changed from 1 Jun 2013 to 1 Feb 2015 as reported by ClinicalTrials.gov.
- 17 Jul 2013 Planned initiation date changed from 1 Feb 2013 to 1 Oct 2014 as reported by ClinicalTrials.gov.
- 17 Jul 2013 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.